21st International AIDS Conference (AIDS 2016)


The Future of Hepatitis C Treatment

September 8, 2016


Hepatitis C History

Hepatitis C History

Hepatitis C (HCV) is a global epidemic with different genotypes of the virus more prevalent in specific regions of the world, explained Jurgen K. Rockstroh, M.D., of University of Bonn, Germany, at the 21st AIDS Conference in Durban, South Africa. HCV was discovered in 1989, with the first anti-HCV therapy approved by the U.S. Food and Drug Administration (FDA) two years later and the first drug combination (interferon and ribavirin) to combat the virus approved in 1998.

These drugs work mainly against genotype 1, which is common in the Americas and Northern Europe. However, few drugs act against genotype 3, which is especially prevalent in South Asia, or other genotypes commonly found in low- and middle-income countries.

Credit: MattZ90 for iStock via Thinkstock.

Get Started

This article was provided by It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.